Sylentis Preps to Move Glaucoma Drug into Phase II Next Year | GenomeWeb

This article has been updated to correct details regarding SYL1001's development timeline.

Spanish RNAi drug developer Sylentis is gearing up to begin a phase II trial of its investigational glaucoma treatment SYL040012, which could start as soon as by the end of the year, Gene Silencing News has learned.

At the same time, the company plans to begin a second phase I trial of an RNAi-based treatment for dry eye-associated pain, called SYL1001, later this year, according to a Sylentis spokeswoman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.